COVI-VAC

BIOLOGICAL2 trials

Sponsors

Codagenix, Inc

Conditions

COVID-19SARS-CoV-2

Phase 1

Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19

CompletedNCT04619628

Codagenix, IncCOVID-19

Start: 2020-12-11End: 2022-05-30Updated: 2022-06-28

Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19

CompletedNCT05233826

Codagenix, IncCOVID-19, SARS-CoV-2

Start: 2022-04-14End: 2022-12-22Updated: 2023-01-13

Related Papers

1938. CoviLiv™, a Novel Intranasal Live-Attenuated COVID-19 Vaccine Candidate, Induces Robust Humoral and Cellular Immunity in First-In-Human Clinical Trial CDX-CoV-001

Open Forum Infectious Diseases2023-11-273 citations